Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Large Growth in Short Interest

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) saw a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 13,390,000 shares, an increase of 9.0% from the August 15th total of 12,280,000 shares. Based on an average daily volume of 2,140,000 shares, the short-interest ratio is presently 6.3 days.

Citius Pharmaceuticals Price Performance

NASDAQ CTXR traded up $0.01 on Wednesday, reaching $0.51. 414,077 shares of the company’s stock traded hands, compared to its average volume of 1,491,298. Citius Pharmaceuticals has a 12 month low of $0.48 and a 12 month high of $1.07. The stock has a 50-day simple moving average of $0.71 and a 200 day simple moving average of $0.71. The stock has a market cap of $92.14 million, a PE ratio of -2.13 and a beta of 1.61.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). As a group, analysts anticipate that Citius Pharmaceuticals will post -0.21 EPS for the current year.

Analyst Ratings Changes

CTXR has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of Citius Pharmaceuticals in a research report on Friday, May 31st. EF Hutton Acquisition Co. I upgraded shares of Citius Pharmaceuticals to a “strong-buy” rating in a research report on Monday, July 15th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CTXR. BNP Paribas Financial Markets grew its holdings in shares of Citius Pharmaceuticals by 88.5% in the first quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock worth $62,000 after purchasing an additional 32,686 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Citius Pharmaceuticals by 1.5% in the first quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company’s stock worth $6,286,000 after purchasing an additional 104,889 shares during the last quarter. Arkadios Wealth Advisors grew its holdings in shares of Citius Pharmaceuticals by 50.0% in the second quarter. Arkadios Wealth Advisors now owns 150,000 shares of the company’s stock worth $88,000 after purchasing an additional 50,000 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Citius Pharmaceuticals in the second quarter worth approximately $69,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Citius Pharmaceuticals in the second quarter worth approximately $118,000. 16.88% of the stock is currently owned by institutional investors.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.